TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33559444
Drug: Epidural nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural nerve block with 20 mL 0.375% ropivacaine 30 min before anesthesia induction
Study: 33548080
Drug: LA-enriched diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-enriched diet (sunflower oil, 30-50 mL, 62-63% LA)
Study: 33548080
Drug: ALA-enriched diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-enriched diet (Camelina sativa oil, 30-50 mL, 30-35% ALA)
Study: 32124625
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg tablet twice a day for 3 months
Study: 32124625
Drug: Transcutaneous Tibial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous Tibial Nerve Stimulation (TTNS) daily for 3 months
Study: 34865304
Drug: Metformin (PCOS-M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (PCOS-M)
Study: 33536385
Drug: Vonoprazan-based second-line
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan-based second-line therapy
Study: 33127971
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment in PCOS patients (PCOS-T)
Study: 35525262
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy group (optimal medical therapy with primary PCI not performed)
Study: 35734811
Drug: Telenursing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telenursing intervention (telephone calls twice a week for the first six weeks, then once a week until week 12)
Study: 33256694
Drug: Specific sensorimotor
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific sensorimotor treatment (SMT)
Study: 33820711
Drug: Repetitive facilitative
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive facilitative exercise (RFE) and botulinum toxin type A (BoNT‐A) injection
Study: 34650303
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo without Nr‐CWS combined with normal saline
Study: 35802640
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (FADs and SBC activities).
Study: 35802640
Drug: Neither treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither treatment (control group).
Study: 34050932
Drug: FIASMA medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIASMA medication
Study: 34050932
Drug: No FIASMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No FIASMA medication
Study: 32790036
Drug: Gaze-contingent music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaze-contingent music reward therapy (8 sessions)
Study: 35294545
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to temozolomide treatment
Study: 35294545
Drug: Temozolomide treatment
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide treatment alone (control)
Study: 35861630
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg once daily for 104 weeks
Study: 35861630
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 104 weeks
Study: 34880344
Drug: Topical Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Anesthesia (TA) 20% benzocaine
Study: 35606238
Drug: Endorsement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endorsement of the vaccine from the pictured doctor (Poster M)
Study: 33427091
Drug: Category 1
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Category 1 anti-tubercular treatment with additional prednisolone
Study: 33427091
Drug: Conventional anti-tubercular
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti-tubercular treatment alone (Control)
Study: 34112063
Drug: Emotion Regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion Regulation Therapy for ICs (ERT‐C)
Study: 35647184
Drug: High Power
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Power Laser Therapy (HPLT) for 3 weeks
Study: 35647184
Drug: Conventional physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy program (ultrasound therapy, moist heat pack, and home exercises) for 3 weeks
Study: 34248142
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies
Study: 34248142
Drug: Small-molecule inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-molecule inhibitors
Study: 34248142
Drug: DC vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC vaccines
Study: 34248142
Drug: TLR agonists
Normalized name: TLR-AD1
DrugBank: TLR-AD1 (DB18241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR agonists
Study: 32517674
Drug: Prevail Managers
Normalized name: Prevail Injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevail Managers programme (communication skills, problem formulation, and problem-solving skills)
Study: 38129117
Drug: Telitacicept 80
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telitacicept 80 mg
Study: 38129117
Drug: Telitacicept 160
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telitacicept 160 mg
Study: 38129117
Drug: Telitacicept 240
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telitacicept 240 mg
Study: 35844038
Drug: Telitacicept (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telitacicept (all doses)
Study: 34377197
Drug: Dexamethasone and
Normalized name: dexamethasone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone and dexmedetomidine combination
Study: 32812388
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.25 mg/kg diluted to 5 ml with 0.9% saline)
Study: 32812388
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml of 0.9% saline)
Study: 34252374
Drug: Adjuvant CapOx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CapOx (intravenous oxaliplatin 130 mg/m2 on day one of each 21 day cycle plus oral capecitabine 1000 mg/m2 twice a day)
Study: 34252374
Drug: Adjuvant SOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant SOX (intravenous oxaliplatin 130 mg/m2 on day one of each 21 day cycle plus oral S-1 40-60 mg twice a day)
Study: 34252374
Drug: Perioperative SOX
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative SOX (intravenous oxaliplatin 130 mg/m2 on day one of each 21 day cycle plus oral S-1 40-60 mg twice a day for three cycles preoperatively and five cycles postoperatively followed by three cycles of S-1 monotherapy)
Study: 34119628
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without statin treatment
Study: 32726529
Drug: RSV fusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RSV fusion (F) protein nanoparticle vaccine
Study: 33751401
Drug: IBI301 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI301 plus CHOP (375 mg/m2)
Study: 33751401
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus CHOP (375 mg/m2)
Study: 32683732
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy in addition to standard dermatology treatment
Study: 32683732
Drug: Standard dermatology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dermatology treatment only (Control)
Study: 33722518
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A treatment in addition to oral medication (B+ group)
Study: 33722518
Drug: Oral medication
Normalized name: Oral Medication Syringe 3mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication only (B- group)
Study: 33481179
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium sulfate 1 mL/kg/day for 1 month
Study: 33481179
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium sulfate
Study: 35429739
Drug: Immersive psychosocial
Normalized name: OCTOCRYLENE 10 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL LOTION [Eucerin Face immersive Hydration]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive psychosocial training program and 10-min daily exercise (36 days total; n = 23; depressed at baseline n = 14)
Study: 39141379
Drug: Vergence/accommodative therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vergence/accommodative therapy
Study: 36260859
Drug: mRNA-1273 vaccine
Normalized name: SARS-CoV-2 mRNA-1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 vaccine (25-μg injections, two doses, administered 28 days apart)
Study: 36260859
Drug: mRNA-1273 vaccine
Normalized name: SARS-CoV-2 mRNA-1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 vaccine (25-μg injections, two doses)
Study: 34767575
Drug: Blended cognitive-behavioural
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended cognitive-behavioural therapy (bCBT)
Study: 34767575
Drug: Face-to-face cognitive-behavioural
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive-behavioural therapy (ftfCBT)
Study: 33564849
Drug: Heterogeneity in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterogeneity in symptoms and treatments
Study: 34231956
Drug: Conventional freehand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional freehand dental implant placement
Study: 34231956
Drug: Dynamic computer-aided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic computer-aided implant surgery (CAIS)
Study: 34231956
Drug: Static computer-aided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static computer-aided implant surgery (CAIS)
Study: 32184121
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 40 mg/m2 plus radiation therapy (RT)
Study: 32184121
Drug: Cetuximab (CTX)
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab (CTX) 250 mg/m2 plus a loading dose of 400 mg/m2 plus radiation therapy (RT)
Study: 33000390
Drug: Computerized decision
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized decision support alert for anticoagulation prescription
Study: 33061398
Drug: Low-dose simvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose simvastatin (≤20 mg/day)
Study: 33061398
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (40 mg/day for 6 weeks, then 80 mg/day for 6 weeks)
Study: 35688116
Drug: Technology group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology group (tablet use)
Study: 32174840
Drug: Salbutamol administration
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol administration
Study: 32179393
Drug: Ultrasound-guided erector
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided erector spinae plane block (ESPB) with 25 ml of 0.5% ropivacaine
Study: 33395690
Drug: Environmental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental treatments with diverse microbial communities
Study: 34665507
Drug: all other
Normalized name: ALL OTHER THERAPEUTIC PRODUCTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: all other formulations
Study: 32134129
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (RBC top-up transfusion to 12 g/dL)
Study: 33412339
Drug: Carnoy's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnoy's solution applied for 5 minutes after surgical excision
Study: 33412339
Drug: Surgical excision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical excision without Carnoy's solution
Study: 35857811
Drug: Switchers (those
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switchers (those who switched to the other antipsychotic)
Study: 35857811
Drug: Stayers (those
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stayers (those who remained on the same compound)
Study: 34120366
Drug: Topiramate treatment
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate treatment
Study: 35906015
Drug: Persuasive messages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persuasive messages focusing on vaccine safety
Study: 33502090
Drug: Empagliflozin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10, 25 mg)
Study: 34260836
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (investigator's choice from 10 options)
Study: 33782244
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline injection in the same level at the control side)
Study: 36050695
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA)
Study: 36050695
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day olive oil (placebo)
Study: 36087395
Drug: Lanreotide autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide autogel 120 mg (LAN)
Study: 33978350
Drug: LDA +
Normalized name: Levodopa and Carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDA + L-Arg (3g) + Mg (350 mg) + Sal (100 mg)
Study: 34244279
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy (LT) delivered via a portable device, daily for 30 min at medium intensity for 8 weeks
Study: 36154518
Drug: Bright White
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright White Light (BWL) therapy at 10,000 lux, applied daily between the second and eighth days of chemotherapy
Study: 36154518
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BWL therapy)
Study: 36154518
Drug: Bright White
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright White Light (BWL) therapy
Study: 33916497
Drug: Clinically indicated
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically indicated peripheral intravenous replacement (CIPIR)
Study: 34427681
Drug: Lung cancer
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung cancer screening with low-dose computed tomography (LDCT)
Study: 32745092
Drug: Aspirin 81-mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 81-mg twice daily
Study: 32745092
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) enoxaparin 30-mg twice daily
Study: 33938709
Drug: Intralesional Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Vitamin D3 injection
Study: 33938709
Drug: Intralesional Candida
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Candida Albicans Antigen injection
Study: 34036177
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) treatment
Study: 33170239
Drug: Omega-3s (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3s (1 g/d)
Study: 33860587
Drug: Propolis plus
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis plus Hyoscyamus niger L. methanolic extract syrup (1.6 mg of extract and 450 mg of propolis per 10 mL, administered three times a day for 6 days)
Study: 35996188
Drug: No TEAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TEAS treatment (Control)
Study: 34061314
Drug: Centhaquine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centhaquine (0.01 mg/kg) administered in 100 mL of normal saline infusion over 1 h
Study: 33393377
Drug: Treatment intervention
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment intervention
Study: 32508141
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of contingency information and fear appeal
Study: 34034748
Drug: Postprandial triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial triglyceride (PTG) concentration during oral fat tolerance testing (OFTT)
Study: 39513526
Drug: Alkylating agents
Normalized name: ALKYLATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agents
Study: 36326664
Drug: Treatment Foster
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Foster Care Oregon (TFCO)
Study: 35180096
Drug: Manipulation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation Therapy (MT)
Study: 35710235
Drug: Tailored exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored exercise and manual therapy
Study: 33673568
Drug: fortified sachet
Normalized name: fosfomycin
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fortified sachet (vitamin D and calcium) and powdered milk plus periodontal therapy during pregnancy (early PT) (n = 17)
Study: 34690787
Drug: OV101 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OV101 5 mg QD (n = 8)
Study: 34690787
Drug: OV101 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OV101 5 mg BID (n = 8)
Study: 34690787
Drug: OV101 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OV101 5 mg TID (n = 7)
Study: 34690787
Drug: OV101 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: OV101 (all doses)
Study: 32545478
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of cocoa-rich chocolate (99% cocoa) daily for six months
Study: 35929990
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C (1.5 g/kg/d, intravenously for 3 hours from D1 to D3) plus FOLFOX ± bevacizumab
Study: 35929990
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C plus FOLFOX ± bevacizumab
Study: 35929990
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C plus chemotherapy
Study: 32479750
Drug: Acetazolamide 125
Normalized name: acetazolamide 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 125 mg twice daily
Study: 33208593
Drug: Higher CysC
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher CysC concentration (≥0.78mg/L) in patients with higher hsCRP concentrations (≥4.8ng/mL)
Study: 33287642
Drug: Moderate observational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate observational caffeine intake from coffee (121 to 180 mg/day)
Study: 33287642
Drug: Moderate observational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate observational caffeine intake from coffee (301 to 360 mg/day)
Study: 32329766
Drug: Intramuscular naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular naloxone
Study: 36419020
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 2 months
Study: 33831589
Drug: Parenteral opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral opioids as labor analgesia
Study: 32802108
Drug: Glycyrrhiza glabra
Normalized name: Glycyrrhiza glabra
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhiza glabra syrup (5 cc, two times a day)
Study: 32802108
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg tablets every 8 hours)
Study: 36107549
Drug: Ultrasound-guided serratus
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided serratus anterior plane block (SAPB) with 20 mL of 0.25% bupivacaine + general anesthesia
Study: 32875933
Drug: Matcha green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matcha green tea powder (3x1 gram capsules per day for three weeks)
Study: 33428281
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg subcutaneous injections at weeks 0, 4, and 16
Study: 32112738
Drug: Camrelizumab 3
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 3 mg/kg intravenously every 2 or 3 weeks
Study: 34992667
Drug: Butorphanol 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.02 mg/kg